Eosinophilic Pneumonia Treatment Market By Disease Classification (Chronic Eosinophilic Pneumonia [CEP], Acute Eosinophilic Pneumonia [AEP]); By Drug Class (Corticosteroids, Biologic Therapies/Monoclonal Antibodies, Immunosuppressants & Other Supportive Therapies); By Route of Administration (Oral Administration, Parenteral Administration); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Online Pharmacies); By End User (Hospitals & Specialty Clinics, Home Healthcare); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are Steroid-Sparing Biologics and Relapse Care Redefining the Eosinophilic Pneumonia Treatment Market?

The Global Eosinophilic Pneumonia Treatment Market was valued at USD 1.16 billion in 2025 and is projected to reach USD 1.86 billion by 2032, expanding at a CAGR of approximately 6.98% during 2026–2032.

 

The Eosinophilic Pneumonia Treatment Market covers the medicines and clinical therapies used to manage acute and chronic eosinophilic pneumonia, a rare group of inflammatory lung disorders caused by abnormal accumulation of eosinophils in the lungs. About 50% of CEP patients have asthma, increasing the need for continued respiratory management. Diagnosis commonly involves chest imaging, blood testing, and bronchoalveolar lavage. BAL eosinophils typically exceed 25% in AEP and 40% in CEP.

 

Treatment spending remains heavily concentrated around systemic corticosteroids such as prednisone and methylprednisolone. In a cohort of 328 AEP patients, around 315 received systemic corticosteroids, approximately 123 underwent steroid pulse therapy, and 285 presented with hypoxia. Median hospitalization was 11 days, while 16 patients required mechanical ventilation and 24 required ICU or high-care admission.

 

Recurrence creates an important long-term treatment opportunity. Around 44.3% of patients have been reported to relapse following steroid reduction or discontinuation, while broader clinical evidence indicates that up to 50% of CEP patients may require long-term low-dose oral or high-dose inhaled corticosteroids. A recent multicentre study involving 79 steroid-treated CEP patients found 35 relapses, highlighting the persistence of maintenance-treatment needs.

 

AstraZeneca is an important company in this treatment landscape through Fasenra (benralizumab), a monoclonal antibody technology that targets the IL-5 receptor alpha on eosinophils and promotes rapid eosinophil depletion. North America, led by the United States, represents the leading regional treatment market due to strong access to pulmonology specialists, hospital-based diagnostic services, advanced respiratory care, and broader availability of biologic therapies for eosinophil-driven diseases.

 

Overall, the market is moving from short-term corticosteroid control toward a broader treatment model that includes acute respiratory stabilization, relapse management, and selective use of targeted biologic technologies for persistent eosinophilic inflammation.

 

Which Subsegments Are Leading and Growing Fastest in the Eosinophilic Pneumonia Treatment Market?

By Disease Classification: Relapsing CEP Defines the Long-Term Treatment Pool

Leading Subsegment – Chronic Eosinophilic Pneumonia (CEP)

Chronic Eosinophilic Pneumonia accounts for an estimated 64% share of the Eosinophilic Pneumonia Treatment Market, representing approximately USD 0.742 billion in 2025, and is projected to expand at a CAGR of 7.45% during 2026–2032. CEP is a distinct eosinophilic lung disorder marked by an abnormal accumulation of eosinophils in lung tissue. Its recurring nature and frequent need for prolonged corticosteroid therapy, clinical monitoring, and emerging biologic treatment options sustain its dominant position within the treatment landscape.

 

By Drug Class: Corticosteroids Lead as Steroid-Sparing Biologics Gain Ground

Leading Subsegment – Corticosteroids

Corticosteroids hold an estimated 68% share, representing approximately USD 0.789 Corticosteroids account for an estimated 68% share of the Eosinophilic Pneumonia Treatment Market, representing approximately USD 0.789 billion in 2025, and are projected to expand at a CAGR of 5.85% during 2026–2032. Their leading position is supported by their role as the primary treatment for acute and chronic eosinophilic pneumonia. Corticosteroids can rapidly suppress pulmonary inflammation and reduce eosinophil accumulation, helping improve respiratory symptoms and clinical outcomes across a broad patient population.

Fastest-Growing Subsegment – Biologic Therapies / Monoclonal Antibodies

Biologic therapies represent an estimated 21% market share, valued at approximately USD 0.244 billion in 2025, and are projected to register the fastest CAGR of 11.25% during 2026–2032. Their expanding role is tied to targeted, steroid-sparing treatment for patients with relapsing or corticosteroid-dependent eosinophilic pneumonia, particularly chronic eosinophilic pneumonia. Monoclonal antibodies targeting eosinophilic inflammatory pathways are gaining clinical relevance by helping reduce repeated corticosteroid exposure and supporting longer-term disease control in difficult-to-manage cases.

 

By Route of Administration: Oral Therapy Anchors Maintenance as Injectables Accelerate

Leading Subsegment – Oral Administration

Oral administration holds an estimated 57% market share, valued at approximately USD 0.661 billion in 2025, and is projected to expand at a CAGR of 5.90% during 2026–2032. Its leading position is supported by the widespread use of systemic corticosteroids such as prednisone as the first-line and mainstay treatment for eosinophilic pneumonia. Oral corticosteroids can provide rapid improvement in respiratory symptoms and lung imaging findings, reinforcing their central role in treatment across both acute and chronic cases.

Fastest-Growing Subsegment – Parenteral Administration

Parenteral administration accounts for an estimated 43% share of the eosinophilic pneumonia market, valued at approximately USD 0.499 billion in 2025, and is projected to register the faster CAGR of 8.45% during 2026–2032. Its strong position is linked to the use of intravenous glucocorticoids in severe or acute cases, particularly when patients present with respiratory failure or severe hypoxemia. Rapid systemic delivery makes parenteral therapy especially important in hospital and intensive-care settings where immediate clinical intervention is required.

 

By Distribution Channel: Hospital Access Meets Specialty Biologic Support

Leading Subsegment – Hospital Pharmacies

Hospital pharmacies hold an estimated 49% share, valued at approximately USD 0.568 billion in 2025, and are expected to register a CAGR of 6.55% during 2026–2032. Their strong position reflects the hospital-based management of moderate to severe eosinophilic pneumonia cases. Hospital pharmacy teams support corticosteroid administration, medication review for drug-induced triggers, dose adjustments, and therapy monitoring. Their involvement is particularly important for hospitalized patients requiring rapid treatment initiation, close clinical observation, and coordinated management of recurrent or complicated cases.

Fastest-Growing Subsegment – Specialty Pharmacies

Specialty pharmacies account for an estimated 31% share, valued at approximately USD 0.360 billion in 2025, and are projected to post the fastest CAGR of 9.25% during 2026–2032. Their role is particularly important in managing complex and high-cost therapies for rare conditions such as eosinophilic pneumonia. These pharmacies coordinate insurance approvals, provide patient education, support treatment adherence, and help patients navigate specialized medication requirements, positioning them as an increasingly important channel for long-term therapy management.

 

By End User: Hospital Expertise Extends Into Home Recovery

Leading Subsegment – Hospitals & Specialty Clinics

Hospitals and specialty clinics hold an estimated 82% share of the Eosinophilic Pneumonia Treatment Market, representing approximately USD 0.951 billion in 2025, and are projected to register a CAGR of 6.75% during 2026–2032. Their strong position reflects the need for specialized diagnosis, corticosteroid administration, respiratory monitoring, and management of severe or recurring cases. Hospitals also provide intensive respiratory support for acute eosinophilic pneumonia, while specialty clinics oversee follow-up care, treatment adjustments, and relapse prevention for chronic patients.

Fastest-Growing Subsegment – Home Healthcare

Home healthcare accounted for an estimated 18% share of the Eosinophilic Pneumonia Treatment Market, valued at approximately USD 0.209 billion in 2025, and is projected to record the fastest CAGR of 8.10% during 2026–2032. Home-based care supports patients recovering from eosinophilic pneumonia through clinical monitoring, corticosteroid therapy assistance, oxygen support, respiratory assessment, and follow-up care. Its expanding role reflects the shift toward continued treatment outside hospitals, particularly for stable patients requiring longer recovery and medication supervision.

 

By Geography: North America Leads as Asia-Pacific Broadens Treatment Access

Leading Region – North America

North America accounts for an estimated 39% share of the global eosinophilic pneumonia treatment market, valued at approximately USD 0.452 billion in 2025, and is projected to expand at a CAGR of 6.45% during 2026–2032. Regional adoption is supported by advanced healthcare infrastructure, strong diagnostic capabilities, wider access to specialist respiratory care, and a high concentration of biopharmaceutical developers. Continued clinical research and access to targeted therapies are also strengthening treatment availability across the United States and Canada.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounts for an estimated 23% share of the eosinophilic pneumonia treatment market, equivalent to approximately USD 0.267 billion in 2025, and is projected to record the fastest regional CAGR of 8.65% during 2026–2032. Treatment adoption across the region is advancing with improvements in healthcare infrastructure, wider clinical awareness, and stronger diagnostic capabilities. Established medical hubs in China, Japan, South Korea, India, and Australia are also improving patient access to specialist respiratory care and modern therapeutic options.

 

Which Company Is Best Positioned in the Eosinophilic Pneumonia Treatment Market?

AstraZeneca – Fasenra Builds a Platform for Steroid-Sparing Respiratory Care

AstraZeneca is one of the most strategically positioned companies in the eosinophilic pneumonia treatment landscape because of its eosinophil-targeted biologic platform, particularly Fasenra (benralizumab). Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and recruits natural killer cells to trigger apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most treated patients. AstraZeneca reports that Fasenra is approved in more than 80 countries for severe eosinophilic asthma and has been prescribed to more than 120,000 patients globally, providing the company with an established commercial and clinical platform in eosinophil-driven respiratory disease.

Its relevance to eosinophilic pneumonia is particularly important in recurrent or corticosteroid-dependent chronic eosinophilic pneumonia, where long-term steroid exposure remains a major treatment challenge. Published clinical evidence shows that more than half of some CEP patient groups can relapse during corticosteroid tapering or withdrawal. In one reported case, benralizumab enabled corticosteroid discontinuation while keeping CEP, asthma, and associated airway disease controlled. More recent evidence reported a relapsing CEP patient who remained relapse-free for over two years with complete eosinophil suppression after switching to benralizumab and establishing an individualized six-month maintenance regimen. Another steroid-dependent eosinophilic pneumonia case showed that benralizumab allowed prednisolone reduction to 5 mg per day without disease relapse.

AstraZeneca therefore has an important technology position through direct IL-5Rα targeting and eosinophil depletion, although Fasenra should not be described as an approved standard treatment specifically for eosinophilic pneumonia. Its current role in this disease is mainly supported by emerging clinical evidence and off-label use in difficult recurrent cases.

Other Relevant Companies and Their Roles

• GSK – Nucala (mepolizumab): Provides an anti-IL-5 monoclonal antibody platform that reduces eosinophil production and survival; published CEP cases have shown corticosteroid withdrawal and prolonged relapse-free control, including one patient maintained for 2.5 years on mepolizumab.

• Sanofi & Regeneron – Dupixent (dupilumab): Target the IL-4 receptor alpha pathway, blocking IL-4 and IL-13 signaling involved in type-2 inflammation; the therapy has broad experience across eosinophilic and allergic disorders and has been used selectively as a steroid-sparing biologic in eosinophilic lung disease.

• Generic Corticosteroid Manufacturers: Remain critical to the treatment base through widely available prednisone and methylprednisolone, which continue to form the first-line pharmacological backbone for both acute and chronic eosinophilic pneumonia.

• Hospital Injectable Drug Suppliers: Support severe AEP management through intravenous corticosteroids and other supportive medicines used when patients present with marked hypoxia or respiratory deterioration.

• Specialty Biologic Manufacturers: Are increasingly relevant as recurrent CEP management shifts toward steroid-sparing anti-eosinophil and type-2 inflammation therapies, especially for patients who experience repeated relapse or corticosteroid toxicity.

 

Analyst Commentary: Where Will Relapse Prevention and Steroid-Sparing Biologics Create the Next Market Opportunity?

The eosinophilic pneumonia treatment market is gradually shifting from prolonged corticosteroid dependence toward more targeted management of eosinophilic inflammation. The strongest opportunities are emerging around steroid-sparing biologics, IL-5 and IL-5 receptor-targeted therapies, relapse-prevention strategies, and specialist respiratory care for recurrent chronic eosinophilic pneumonia. Greater use of precision biologics, improved patient monitoring, and earlier identification of corticosteroid-dependent cases are expected to reshape treatment pathways over the forecast period.

 

Eosinophilic Pneumonia Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.16 Billion
Revenue Forecast in 2032	USD 1.86 Billion
Overall Growth Rate	CAGR of 6.98% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Disease Classification, By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Geography
By Disease Classification	Chronic Eosinophilic Pneumonia (CEP), Acute Eosinophilic Pneumonia (AEP)
By Drug Class	Corticosteroids, Biologic Therapies / Monoclonal Antibodies, Immunosuppressants and Other Supportive Therapies
By Route of Administration	Oral Administration, Parenteral Administration
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail and Online Pharmacies
By End User	Hospitals & Specialty Clinics, Home Healthcare
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	High prevalence of eosinophilic inflammation in chronic respiratory disease, recurrent and corticosteroid-dependent CEP, growing adoption of steroid-sparing biologic therapies, increasing specialist respiratory-care capacity, rising demand for relapse management, improved diagnosis through imaging and bronchoalveolar lavage, and expansion of targeted IL-5/IL-5 receptor therapies
Customization Option	Available upon request